Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Nov 16, 2009
Study Will Explore the Long-Term Safety and Efficacy of Inhaled Ciprofloxacin in a Severe Respiratory Disease with Unmet Medical Needs
Aradigm Announces Third Quarter 2009 Financial Results
Nov 05, 2009
Inhaled Liposomal Ciprofloxacin Program is Progressing; Milestone Payment and Royalties Will Be Received Upon Zogenix Planned January 2010 Product Launch
Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
Oct 22, 2009
HAYWARD, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the 2009 Annual BIO Investor Forum on Wednesday, October 28, 2009, at 12:30 p.m. Pacific time (3:30 p.m.
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
Sep 14, 2009
Aradigm is presenting results from its Phase 2a clinical trial in non-cystic fibrosis bronchiectasis patients at the 2009 European Respiratory Society (ERS) Annual Congress.Additionally, Aradigm is presenting summary data on the pharmacokinetics of its once-daily inhaled liposomal ciprofloxacin formulation (CFI) in CF patients and healthy volunteers.
Aradigm Announces Second Quarter 2009 Financial Results
Aug 06, 2009
HAYWARD, Calif., Aug 06, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2009. No revenue was recorded for the second quarter of 2009, compared with revenue of $54,000 for the second
Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe
Aug 05, 2009
HAYWARD, Calif., Aug 05, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that the European Medicines Agency (EMEA) granted Orphan Drug Designation to the Company's inhaled liposomal ciprofloxacin drug product candidate for the treatment of lung infections
Zogenix Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM) DosePro(TM)
Aug 04, 2009
Sumavel DosePro Expected to Be Commercially Available in January 2010
Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
Jul 23, 2009
HAYWARD, Calif., Jul 23, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application.
Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
Jul 16, 2009
Aradigm to Earn $4 Million Milestone Payment Upon Commercial Launch and Royalties on Sales
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference
Jun 11, 2009
Both Studies Demonstrated Pharmacokinetics Supporting Once-Daily Dosing, with Significant Reduction in Bacterial Infection in Cystic Fibrosis Patients
Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society
May 14, 2009
Studies Demonstrate Significant Reduction in Bacterial Infection Following Once-Daily Treatment with Inhaled Liposomal Ciprofloxacin in Both Indications
Aradigm Announces First Quarter 2009 Financial Results
May 12, 2009
HAYWARD, Calif., May 12, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2009. No revenue was recorded for either the first quarter of 2009 or the first quarter of 2008.
Aradigm Announces Fourth Quarter 2008 and Full Year Financial Results
Mar 25, 2009
HAYWARD, Calif., Mar 25, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2008. The Company recorded no revenue in the fourth quarter, compared with revenue of $18,000 for the fourth
Webcast Alert: Lippert/Heilshorn Life Sciences Conference Presentation (Aradigm)
Mar 24, 2009
NEW YORK, Mar 24, 2009 (BUSINESS WIRE) -- Aradigm (ARDM) announces the following Webcast: What: Lippert/Heilshorn Life Sciences Conference Presentation When: March 26, 2009 @ 2:00 PM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=142720 How: Live over the Internet -- Simply log on
Aradigm Announces $400,000 Additional Registered Direct Offering
Feb 25, 2009
HAYWARD, Calif., Feb 25, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) ("Aradigm") announced today that it has entered into a definitive agreement with an investor to sell 4,000,000 shares of its common stock for gross proceeds of $400,000, before deducting placement agent fees and
Aradigm Announces $4.1 Million Registered Direct Offering
Feb 23, 2009
HAYWARD, Calif., Feb 23, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") announced today that Aradigm entered into definitive agreements with investors to sell up to approximately 40.7 million shares of its common stock for gross proceeds of approximately $4.1 million, before
Aradigm Reports Positive Phase 2 Results with Inhaled Liposomal Ciprofloxacin Hydrochloride in Patients with Bronchiectasis
Jan 21, 2009
Study demonstrates significant reduction in bacterial infection
following four weeks of once daily inhaled treatment
Aradigm to Present at the 20th Annual Piper Jaffray Health Care Conference on December 2
Nov 24, 2008
HAYWARD, Calif., Nov 24, 2008 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D. will present at the 20 th Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2008, at 11:30 a.m.
Aradigm Announces Third Quarter 2008 Financial Results
Nov 12, 2008
HAYWARD, Calif., Nov 12, 2008 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2008. Revenue for the third quarter was $197,000, compared with revenue of $230,000 for the third quarter of
Aradigm Completes Study of Inhaled Treprostinil with AERx(R) Inhaler
Nov 10, 2008
Lung Rx Makes First Milestone Payment to Aradigm
Displaying 141 - 160 of 234
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.